No Data
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17.
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
Morgan Stanley analyst Patrick Wood maintains $RxSight(RXST.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 51.4% and a
RxSight (RXST) Gets a Buy From Morgan Stanley
RxSight Price Target Raised to $73.00/Share From $72.00 by BTIG
RxSight Price Target Raised to $73.00/Share From $72.00 by
RxSight Is Maintained at Buy by BTIG
RxSight Is Maintained at Buy by
BTIG Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $73
BTIG analyst Ryan Zimmerman maintains $RxSight(RXST.US)$ with a buy rating, and adjusts the target price from $72 to $73.According to TipRanks data, the analyst has a success rate of 46.6% and a